Literature DB >> 17984336

Mycobacterium leprae DNA associated with type 1 reactions in single lesion paucibacillary leprosy treated with single dose rifampin, ofloxacin, and minocycline.

Ana Lucia O M Sousa1, Mariane M A Stefani, Gisner A S Pereira, Mauricio B Costa, Paula F Rebello, Maria Katia Gomes, Kazue Narahashi, Thomas P Gillis, James L Krahenbuhl, Celina M T Martelli.   

Abstract

Leprosy affects skin and peripheral nerves, and acute inflammatory type 1 reactions (reversal reaction) can cause neurologic impairment and disabilities. Single skin lesion paucibacillary leprosy volunteers (N = 135) recruited in three Brazilian endemic regions, treated with single-dose rifampin, ofloxacin, and minocycline (ROM), were monitored for 3 years. Poor outcome was defined as type 1 reactions with or without neuritis. IgM anti-phenolic glycolipid I, histopathology, Mitsuda test, and Mycobacterium leprae DNA polymerase chain reaction (ML-PCR) were performed at baseline. chi(2) test, Kaplan-Meir curves, and Cox proportional hazards were applied. The majority of volunteers were adults with a mean age of 30.5 +/- 15.4 years; 44.4% were ML-PCR positive. During follow-up, 14.8% of the patients had a poor clinical outcome, classified as a type 1 reaction. Older age (> or = 40 years), ML-PCR positivity, and lesion size > 5 cm were associated with increased risk. In multivariate analysis, age (> or = 40 years) and ML-PCR positivity remained baseline predictors of type 1 reaction among monolesion leprosy patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17984336

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  5 in total

1.  Risk factors for leprosy reactions in three endemic countries.

Authors:  David M Scollard; Celina M T Martelli; Mariane M A Stefani; Maria de Fatima Maroja; Laarni Villahermosa; Fe Pardillo; Krishna B Tamang
Journal:  Am J Trop Med Hyg       Date:  2014-12-01       Impact factor: 2.345

2.  Potential plasma markers of Type 1 and Type 2 leprosy reactions: a preliminary report.

Authors:  Mariane M Stefani; Jackeline G Guerra; Ana Lucia M Sousa; Mauricio B Costa; Maria Leide W Oliveira; Celina T Martelli; David M Scollard
Journal:  BMC Infect Dis       Date:  2009-05-27       Impact factor: 3.090

3.  Can baseline ML Flow test results predict leprosy reactions? An investigation in a cohort of patients enrolled in the uniform multidrug therapy clinical trial for leprosy patients in Brazil.

Authors:  Emerith Mayra Hungria; Regiane Morillas Oliveira; Gerson Oliveira Penna; Lúcio Cartaxo Aderaldo; Maria Araci de Andrade Pontes; Rossilene Cruz; Heitor de Sá Gonçalves; Maria Lúcia Fernandes Penna; Ligia Regina Franco Sansigolo Kerr; Mariane Martins de Araújo Stefani; Samira Bührer-Sékula
Journal:  Infect Dis Poverty       Date:  2016-12-06       Impact factor: 4.520

4.  Identification of clinical, epidemiological and laboratory risk factors for leprosy reactions during and after multidrug therapy.

Authors:  Douglas Eulálio Antunes; Sergio Araujo; Gabriela Porto Ferreira; Ana Carolina Sousa Rodrigues da Cunha; Adeilson Vieira da Costa; Maria Aparecida Gonçalves; Isabela Maria Bernardes Goulart
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-11       Impact factor: 2.743

5.  A Missense LRRK2 Variant Is a Risk Factor for Excessive Inflammatory Responses in Leprosy.

Authors:  Vinicius M Fava; Jérémy Manry; Aurélie Cobat; Marianna Orlova; Nguyen Van Thuc; Nguyen Ngoc Ba; Vu Hong Thai; Laurent Abel; Alexandre Alcaïs; Erwin Schurr
Journal:  PLoS Negl Trop Dis       Date:  2016-02-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.